# A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes

> **NCT04955834** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 344 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Insulin degludec injection
- **DRUG:** Tresiba®

## Key facts

- **NCT ID:** NCT04955834
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-27
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 344 (ESTIMATED)
- **Last updated:** 2021-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04955834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04955834, "A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04955834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*